Immunosuppression without prophylactic antilymphocyte preparations.
1. Triple-drug immunosuppression following third party transfusion can result in graft survival equal to protocols that employ prophylactic antilymphocyte preparations. 2. T1/2 was statistically improved in cadaveric and living-related donor grafts in the CsA era. 3. Patients 65 years and older had an excessive death rate. Younger groups were admixed. Extreme youth was not a risk factor. 4. Black recipients had excessive late graft loss. 5. Diabetic recipients had only a slight decline in graft and patient survival rates. 6. First and multiple graft recipients had similar transplant survival rates. 7. Delayed graft function remains costly in this immunosuppressive scheme.
Pfaff
W W
WW
Department of Surgery, University of Florida College of Medicine, Gainesville.
Patton
P R
PR
Howard
R J
RJ
Brunson
M E
ME
Ramos
E L
EL
Fennell
R S
RS
Peterson
J C
JC
Scornik
J C
JC
D000046:Academic Medical Centers; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D005431:Florida / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology* / Q000379:methods* / Q000401:mortality; D008875:Middle Aged; D012307:Risk Factors; D015996:Survival Rate; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D016572:Cyclosporine